Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobomarsen - Viridian Therapeutics

Next Previous
Drug Profile

Cobomarsen - Viridian Therapeutics

Alternative Names: MRG 106

Latest Information Update: 02 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator miRagen Therapeutics
  • Developer Viridian Therapeutics
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Adult T-cell leukaemia-lymphoma; Mycosis fungoides
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Adult T-cell leukaemia-lymphoma; Amyotrophic lateral sclerosis; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma

Most Recent Events

  • 02 Jul 2024 Discontinued - Phase-I for Adult T-cell leukaemia-lymphoma (Monotherapy, Second-line therapy or greater) in USA (IV) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)
  • 02 Jul 2024 Discontinued - Phase-I for Adult T-cell leukaemia-lymphoma (Monotherapy, Second-line therapy or greater) in USA (SC) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)
  • 02 Jul 2024 Discontinued - Phase-I for Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater) in USA (IV) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top